KRI1: A Protein Involved in Cellular Signaling and Disease (G65095)

KRI1: A Protein Involved in Cellular Signaling and Disease

KRI1 (KRI1_HUMAN), also known as G protein-coupled receptor 1 (GPCR1), is a protein that plays a crucial role in cellular signaling. It is a member of the GPCR family, which includes over 700 different proteins that regulate various cellular processes. KRI1 is expressed in many different tissues and cells in the human body, including the brain, heart, kidneys, and pancreas.

KRI1 is a transmembrane protein, which means that it spans the cell membrane and is associated with the cytosol and the cell surface. It has a long extracellular domain that is involved in its interactions with other proteins, including G伪11, a protein that plays a key role in cell signaling. The transmembrane region of KRI1 contains a catalytic active site, which is responsible for the protein's signaling functions.

KRI1 is involved in a wide range of physiological processes in the human body. One of its main functions is to regulate the production and release of various hormones, including insulin and glucagon. It is also involved in the regulation of pain perception and the production of neurotransmitters, such as dopamine and serotonin.

KRI1 has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. For example, studies have shown that KRI1 is often overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This increase in KRI1 expression is associated with the development of cancer stem cells, which are cancer cells that have the ability to continuously divide and promote the spread of the disease.

Another study has also shown that KRI1 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The research suggests that KRI1 may be a potential drug target or biomarker for these diseases, as blocking the activity of KRI1 may help to treat the symptoms associated with these conditions.

In addition to its involvement in disease, KRI1 is also a potential drug candidate for its own. Studies have shown that KRI1 can be targeted by small molecules, which could make it an attractive target for drug development. One company, called Krios Nanoparticles, has developed a technology that uses nanoparticles to deliver small molecules to cells, including KRI1. This technology has the potential to be a useful tool for drug development, as it allows researchers to test the effectiveness of different small molecules on KRI1 without affecting the cell's normal function.

Overall, KRI1 is a protein that plays a crucial role in cellular signaling and is involved in a wide range of physiological processes in the human body. Its functions include regulating the production and release of hormones, the regulation of pain perception, and the production of neurotransmitters. KRI1 is also involved in the development and progression of several diseases, including cancer and neurodegenerative diseases.

The potential drug target status of KRI1 is an exciting area of research, as it has the potential to be a valuable tool for the development of new treatments for these diseases. By using small molecules to target KRI1, researchers may be able to treat the symptoms associated with these conditions and improve the quality of life for patients.

Protein Name: KRI1 Homolog

The "KRI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KRIT1 | KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85